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Small molecule natural products have aided in the discovery 
and characterization of many proteins critical to the 
progression and maintenance of the cell cycle. Identification of 
the direct target of a natural product gives scientists a tool to 
control a specific aspect of the cell cycle, thus facilitating the 
study of the cell-cycle machinery. 
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Introduction 
Nature has evolved an elegant solution to the complex 
problem of regulating cellular proliferation. With numer- 
ous, constitutive processes occurring in the background 
that contribute to the growth of cells, an impeccable clock 
controls specifically timed events in preparation for cell 
division. Malfunctioning of this clock wreaks cellular 
havoc and is the molecular basis for proliferative disorders 
such as cancer. 
Many of the proteins that regulate critical events of the 
cell-division cycle have been identified. The classical 
genetic approach to understanding protein function in 
cells involves making mutations in genes that alter the 
function of the encoded protein. An alternative approach 
is to alter the function of the protein directly by using a 
cell-permeable ligand that binds to the protein in its intra- 
cellular environment. As with temperature-sensitive 
folding mutations, this chemical approach allows condi- 
tional alteration of function, causing either a loss [l] or 
gain [Z] of function of the intracellular protein. The major 
challenge for this field is the development of methods for 
the identification of cell-permeable ligands for any given 
protein [3]. 
Currently, the most valuable collection of ligands for use 
in the study of protein function are natural products, or, in 
some instances, compounds that are closely related to 
natural products. Many small molecule natural products 
inhibit progression of the cell cycle by binding to a protein 
required for cell division, thus helping to determine the 
function of the protein. Conversely, an understanding of 
cell cycle events helps in understanding the mechanisms 
of action for many cell-cycle inhibitors. Thus, in the field 
of cell-cycle regulation, the marriage of cell biology and 
natural products chemistry has already proven fruitful, 
with continued promise for the future. In this review, we 
first outline the current state of knowledge of the cell 
cycle, before discussing the natural products and their 
derivatives that have illuminated cell-cycle events and 
ones with the potential for doing so. 
The cell cycle 
Two primary events in cell proliferation are DNA replica- 
tion and cell division, the latter resulting in the formation 
of two cells from a single precursor (see [4] for a review of 
the cell cycle). Replication must necessarily precede chro- 
mosomal segregation and cell division to ensure fidelity in 
transmission of all genetic information, The cell cycle has 
been divided into four sequential phases (Fig. 1): Gl is 
the first gap phase in which the cell prepares for DNA 
replication; S phase is the period of DNA synthesis during 
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which a second copy of the entire genome is generated; 
G’2 is a second gap phase in which the cell prepares for 
division; and, finally, M phase or mitosis is the period 
during which the two copies of DNA segregate and the 
cell divides into two genetically identical daughter cells. 
Entrance into and exit out of the cell cycle occurs as a cell 
passes between active proliferation and a quiescent or GO 
state, in which the fundamental metabolism of the cell is 
depressed, including many of its usually active functions 
such as transcription and protein synthesis. Deprivation of 
growth factors can cause a cell to exit into GO, whereas 
stimulation with growth factors can signal a cell to re-enter 
the active cycle. A cell may also exit the cell cycle to 
undergo processes of differentiation or programmed cell 
death (apoptosis) [5,6]. Many complex signals interact to 
determine a cell’s fate, specifying whether it should be 
quiescent, divide, differentiate, or undergo apoptosis. 
The cell-cycle engine and brakes 
The elements responsible for driving the cell cycle from one 
phase to the next are a series of protein kinases and phos- 
phatases that activate and deactivate each other. The cyclin- 
dependent kinases (Cdks) are responsible for 
phosphorylating various substrates critical to cell-cycle pro- 
gression. The levels of the Cdks are invariant throughout 
the cell cycle, but their activities are modulated by their 
interaction with another set of proteins called cyclins, whose 
levels fluctuate. The point in the cell cycle at which the 
various cyclins are expressed at the highest level is some- 
what cell-line dependent and can vary dramatically between 
transformed and non-transformed cells. In general, however, 
the cyclin Ds are associated with Gl, cyclin Es with the Gl 
Figure 1 
to S transition, cyclin As with S phase as well as with the G2 
to M transition, and cyclin Bs with the GZ to M transition 
(Fig. 1). The presence of a Cdk-cyclin complex does not 
ensure activity, however, as the Cdk-cyclin complexes can 
be inhibited by the Cdk inhibitors (CDIs; see below) [7]. 
Gl phase and the Gl/S transition 
Gl is a critical point at which the cell assesses whether it 
should enter another full round of division. It is perhaps 
not surprising, then, that the proteins involved in Gl pro- 
gression are frequently mutated in human cancers, and it 
is now recognized that these proteins are among the most 
attractive targets for the development of new therapeutic 
agents for the treatment of cancer. The progression from 
GO to Gl is triggered by the binding of extracellular 
growth factors to specific cell-surface receptors. Signal 
transduction cascades downstream of these receptors then 
activate various intracellular processes required for prolif- 
eration, including the transcription and translation of 
many cell-cycle-dependent factors [8]. Among these 
factors are the Gl cyclins (predominantly the cyclin D 
family) that form active complexes with various Cdks. 
The Cdk-Gl cyclin complexes release a brake on the cell 
cycle, allowing it to progress forward into S phase. 
S phase, 62 phase, and the G2/M transition 
Driven by the the Cdk-Gl cyclin complexes, the cell pro- 
gresses into S phase where a complicated assembly of 
DNA polymerases, primases, helicases, topoisomerases and 
accessory factors duplicate the genome. Independently, 
replication of the centrosome or microtubule-organizing 
center (MTOC) must also occur to ensure bipolar anchor 
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The cell cycle is driven by an ordered 
activation of various Cdk-cyclin complexes. 
The arrows show the portions of the cell 
cycle in which the particular Cdk-cyclin 
complex is active. Passage through these 
parts of the cell cycle require the activation of 
this complex, which is primarily driven by the 
accumulation of the specific cyclin. 
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sites for mitotic spindle formation. Upon completion of 
DNA synthesis, the cell progresses through G2, a period of 
active protein synthesis in preparation for cell division. 
M phase and the exit from mitosis 
Although a basic understanding of mitosis has existed for 
decades, the details of its regulation have emerged only 
recently. Following activation of a Cdk-cyclin complex 
(CdcZ-cyclin B) and condensation of the chromosomes, 
the paired sister chromatids must be pulled apart by the 
spindle into two distinct daughter cells. Formation of the 
spindle requires reorganization of the microtubule network 
via an increase in the rate of microtubule shrinking and a 
decrease in the rate of growth. The spindle grows from the 
two MTOCs, which contain y-tubulin [9]. A subset of the 
microtubules also attach to the kinetochore of the chromo- 
somes. The kinetochore is a complex of DNA and proteins 
that holds the two sister chromatids together prior to sepa- 
ration [lo]. The microtubule motors dynein and kinesin 
align the chromosomes at the metaphase plate, and, follow- 
ing dissolution of a putative sister-chromatid ‘glue’, drive 
the separation of the sister chromatids. 
Checkpoints 
To ensure the integrity of the cell and its genetic material, 
the events of the cell cycle must occur in a well-defined 
sequence; completion of certain events must precede the 
initiation of others. For example, DNA replication must 
be completed before mitosis begins to ensure that both 
cells receive a complete copy of the genome. Checkpoint 
signaling pathways exist in the cell cycle to ensure the 
proper order and timing of events [ll,lZ]. Checkpoints are 
thought to consist of a sensor that detects the problem, a 
signal transduction cascade that directs the sensor’s 
output, and effecters that then stop transitions in the cell 
cycle by interacting with the cell-cycle machinery. In 
general, checkpoints function to allow time for a process 
(such as DNA replication or repair) to be completed, 
although after some types of DNA damage repair is also 
induced. Checkpoints provide the means by which many 
natural products arrest the cell cycle, as the damage 
inflicted by the natural product is detected and then the 
cell-cycle engine is halted. 
At a critical point at the Gl/S interface (called the restric- 
tion point in multicellular organisms), the cell’s ability to 
complete a full cell cycle, including DNA synthesis, is 
confirmed prior to committing to S phase. In yeast, cell 
size is monitored at this point to determine whether suffi- 
cient nutrients are available to complete the cell cycle 
[13]. The cell is delayed in Gl until it is large enough to 
pass through the checkpoint. 
Genetic analysis has identified several genes whose prod- 
ucts monitor the integrity and replication of DNA [14,15]. 
Studies in both budding and fission yeast have identified 
genes (including, for budding yeast, the RAD and MEC 
genes) whose products are necessary for cell-cycle arrest 
either in Gl or G2 in response to DNA damage and also 
in response to incomplete DNA replication in G2. In 
mammals there is a prominent Gl DNA-damage-depen- 
dent arrest that seems to be mediated by the tumor sup- 
pressor ~53 [16,17]. Although it is not required for normal 
growth, ~53 is essential for sensing DNA damage after 
X-ray irradiation and causing cell-cycle arrest to permit 
DNA repair. 
Clearly, checkpoints must be intimately tied to the regula- 
tory events that drive or halt the cycle. For example, p53 
arrest seems to be mediated by a recently discovered 
family of endogenous CDIs [18] that negatively regulate 
or halt the cell cycle. ~53 induces the transcription and 
subsequent expression of a 21 kD protein, ~21, in 
response to DNA damage [19]. It has been shown that ~21 
interacts with Cdks in complex with different cyclins [ZO], 
preventing their ability to phosphorylate and activate sub- 
strates necessary for Gl progression. The related CDI, 
~‘27, is also capable of causing Cl arrest [21,22]. Mam- 
malian cells also arrest in G2 in response either to DNA 
damage sustained during S phase, or incomplete DNA 
replication [23]. 
A distinct G2 checkpoint may be activated by the inhibi- 
tion of topoisomerase II [24]. Topoisomerases regulate 
the topology of DNA, unwinding DNA during transcrip- 
tion or replication, and condensing it during cell division. 
Whereas topoisomerase I is active constitutively, topoiso- 
merase II expression and activity is highest during G2 
and M phases [25]. Selective inhibition of topoisomerase 
II, in the absence of DNA damage, results in G2 arrest at 
a checkpoint that most probably monitors the ability to 
condense chromosomes. 
A checkpoint also exists in mitosis to monitor mitotic 
spindle formation. A signal arising from incorrectly 
attached kinetochores [26], and possibly also an incom- 
plete spindle structure, prevents chromosome separation 
and mitotic exit. Once the cell passes this last checkpoint, 
it divides and the two daughters reenter Gl. 
Natural product inhibitors of the cell cycle 
Small molecule natural products have aided in disentang- 
ling the complex web of cell-cycle events in several ways. 
Irrespective of their targets, natural products have been 
invaluable as agents to achieve arrests at specific points in 
the cell cycle, allowing synchronization of a population of 
cells. Identification of the direct targets of natural product 
inhibitors of the cells cycle implicates specific proteins or 
activities as being essential to cell-cycle-related functions. 
Components downstream of these direct targets can then 
be identified on the basis of their indirect inhibition by 
the same agent. Once a specific binding interaction is 
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established, a cell-permeable natural product can be used 
to understand the function of its protein target in living 
cells. Exposure of cells to the natural product causes a 
conditional loss of function in the target protein, a result 
similar to that achieved by the use of temperature-sensi- 
tive mutations in the gene encoding a protein of interest. 
Commonly, such mutations result in the unfolding of 
the mutant protein at the non-permissive temperature, 
resulting in loss of the protein’s function. 
Entry into the cell cycle - the GO to Gl transition 
One class of natural products (Fig. 2) warrants brief 
mention prior to discussion of agents that arrest the active 
cell cycle. In response to certain external signals, a cell will 
enter the active cell cycle from a resting GO state. Various 
exogenous growth factors act to stimulate the cell through 
activation of their respective receptors, located on the 
plasma membrane of the cell [27,28]. Many of these recep- 
tors are tyrosine kinases which, upon activation, initiate an 
intracellular signal transduction pathway whose ultimate 
end point is cell proliferation. Some natural products 
inhibit the signal-transduction pathways required for the 
GO to Gl transition. Perhaps the most thoroughly studied 
examples are FK.506 and cyclosporin A, which inhibit the 
T-cell receptor (TCR) pathway through inhibition of cal- 
cineurin [29,30]. The TCR pathway prepares a resting 
(GO) T cell for the cell cycle in part by inducing the syn- 
thesis of interleukin-2 (IL-Z) and the IL-Z receptor, which, 
Figure 2 
when combined, activate a second signaling pathway 
required for T cells to progress through the Gl phase of 
the cell cycle. Other natural products that inhibit the GO to 
Gl transition include radicicol, which inhibits the platelet- 
derived growth factor (PGDF) receptor pathway [31], and 
epiderstatin [32] and reveromycin [33], which inhibit some 
element of the epidermal growth factor (EGF) receptor 
pathway. The PDGF receptor pathway is generally viewed 
as one used by some cells to exit quiescence and enter the 
cell cycle (GO to Gl), whereas the mechanistically related 
EGF receptor pathway has been viewed as facilitating 
further progression through Gl. 
Gl-phase-specific arrest agents 
A molecule that inhibits a process that affects a cell-cycle 
protein, such as its synthesis, post-translational modifica- 
tion, or degradation, tends to be less useful in cell cycle 
studies than an inhibitor that binds to the actual protein 
itself, because other, non-related proteins can be regu- 
lated by the same upstream mechanism. Thus, the degree 
of specificity of an arrest agent may be proportional to its 
functional proximity to actual cell-cycle regulatory events. 
Within the class of Gl arrest agents, at least two inhibitors, 
rapamycin and wortmannin (Fig. 3a), act directly on cell- 
cycle events themselves. Rapamycin, in complex with its 
intracellular binding protein FKBP12, inhibits FRAP 
(FKBP-rapamycin binding protein) [34-361, a signaling 
molecule required for the activation of the downstream 
Cyclosporin A FK-506 
Epiderstatin Radicicol Reveromycin A 
GO to Gl inhibitors. Cyclosporin A and FK506 inhibit the T-cell 
receptor pathway, which in turn prevents the induction of interleukin-2 
(IL-2) and the IL-2 receptor; these molecules activate a pathway that 
drives T cells from GO into Gl Epiderstatin, radicicol and reveromycin 
A all inhibit pathways from GO to Gl that are activated by extracellular 
growth factors. 
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Figure 3 
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Gl -specific arrest agents. (a) Rapamycin and wortmannin inhibit the activation of p70 S6 kinase, thought to be required for progression from Gl 
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Figure 4 
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Gl/S- and S-phase-arrest agents that inhibit DNA synthesis. 
effector molecule p70 S6 kinase and for the inactivation of 
the inhibitor of translation initiation, 4E-BP1 [37]. Further 
downstream in the FRAP pathway are the cyclin-depen- 
dent kinase inhibitors ~21 and ~27. Neither the direct 
action of FRAP nor the precise mechanism by which it 
regulates the levels of ~21 and ~27 are currently known, 
although it appears to involve the regulation of translation 
of specific mRNA transcripts. Wortmannin also prevents 
p70 S6 kinase activation, in this case by inhibiting phos- 
phatidylinositol3-kinase (PI3K) [38-40]. The functions of 
PI3K’s phosphorylated substrates are at present incom- 
pletely defined. Nevertheless, FRAP and PI3K’s common 
downstream target, p70 S6 kinase, is thought to be 
required for Gl progression into S phase [41-43]. Both of 
the natural products have been used widely to identify 
components of the FRAP- and PI3K-dependent signaling 
pathways. Indeed, these pathways were discovered by 
their response to the natural products. 
Another major subset of Gl arrest agents are compounds 
that interfere with the mevalonate metabolic pathway (Fig. 
3b). Mevalonate is the isoprenoid precursor to many essen- 
tial cellular components including cholesterol, dolichol, 
ubiquinone, heme, tRNA, and isoprenylated proteins. 
Inhibitors of HMG-CoA reductase (an enzyme required for 
mevalonate synthesis) such as compactin and lovastatin, 
result in Gl arrest [44]. Several different mevalonate 
requirements exist for cell-cycle progression in Gl. Com- 
pactin causes a very early Gl arrest, most likely related to a 
cholesterol requirement, since addition of cholesterol 
allows the cell to recover and progress [4.5]. Zaragozic acid, 
an inhibitor of squalene synthase, also causes this early Gl 
block by inhibiting cholesterol synthesis (Fig. 3) [46]. 
Products of mevalonate metabolism other than cholesterol 
are also required for Gl progression, since a later Gl block 
is insensitive to the addition of cholesterol [47]. A late Gl 
arrest can also be induced by tunicamycin (Fig. 3) [48,49]. 
Tunicamycin inhibits the first step in the glycosylation of 
proteins, namely, the transfer of N-acetylglucosaminyl-l- 
phosphate to dolichol, an isoprenoid lipid derived from 
mevalonate [SO]. This dolichol requirement strongly sug- 
gests that glycoproteins are essential for progression 
through late stages of Gl [51]. A third requirement derived 
from the mevalonate pathway was revealed by the inability 
of cholesterol and dolichol addition to overcome another 
late compactin block [.52]. Instead, the addition of isopen- 
tenyl adenine was more effective at restoring cell-cycle 
progression [53]. Isopentenyl adenine is an essential 
element in the isoprenylation of proteins. This finding sug- 
gests that isoprenylated proteins have an important role in 
proliferation (Fig. 3), as in the case of the protein Ras, now 
a target for drug development [54,55]. Surprisingly, inhibi- 
tion of mevalonate biosynthesis results in a Gl arrest only, 
implying that none of these same components or functions 
are required in later cell-cycle phases. 
Gl/S-transition and S-phase arrest agents 
Small molecules that cause cell-cycle arrest by affecting 
DNA fall into two classes (Fig. 4). One class of compounds 
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DNA-damaging agents that cause Gl and G2 arrest. 
directly inhibits DNA synthesis by affecting either the repli- 
cation machinery or the nucleotide pool, resulting in arrest at 
the Gl/S interface, or in S phase if the compound is added 
after passage into S phase. The second class causes damage 
to DNA, leading to a Gl or G2 checkpoint-mediated arrest, 
and will be discussed in a later section. 
A majority of the established chemotherapeutic and anti- 
neoplastic agents are synthetic antimetabolites that inhibit 
the synthesis of deoxyribonucleotides, thus preventing 
elongation of nascent polynucleotide chains. Although 
they are not strictly cell-cycle-specific, cells are more sen- 
sitive to their actions in late Gl and S. Representative 
members include methotrexate (an inhibitor of dihydrofo- 
late reductase); 5fluorouraci1, cytarabine, and flucytosine 
(pyrimidine analogs); and 6-mercaptoguanine (a purine 
analog) (Fig. 4) [.56]. Hydroxyurea (HU) also arrests cells 
at the Gl/S interface if they have not yet entered S phase, 
or in S phase if they have [57]. HU inhibits ribonucleotide 
diphosphate reductase, an enzyme that converts ribonu- 
cleotides to deoxyribonucleotides. The fairly immediate 
arrest observed upon addition of these inhibitory com- 
pounds suggests tight coordination between DNA synthe- 
sis and cell-cycle progression. Either there is only a very 
small pool of excess deoxyribonucleotides so that constant 
nucleotide synthesis is required, or there is a monitoring 
system (analogous to cell-cycle checkpoints) that is tightly 
coupled to nucleotide synthesis and quickly senses its 
inhibition. HU is also one of the most effective reagents in 
cell-cycle studies, as it can be used to synchronize cells at 
the Gl/S interface. Removal of HU by simple washing 
allows a population of cells to continue through the cell 
cycle in a synchronized manner. 
Aphidicolin causes S-phase arrest by inhibiting DNA poly- 
merase (Y (Fig. 4) [%I. It inhibits expansion and elongation 
of the replication bubble, but not replication fork forma- 
tion. Mimosine, on the other hand, has been traditionally 
thought to inhibit the formation of replication forks, for- 
mally causing a late Gl arrest. Recent work now suggests 
that mimosine may be affecting the deoxyribonucleotide 
pool in a manner similar to HU, causing S-phase arrest [59]. 
Gl- and GP-phase arrest agents 
Several classes of compounds cause both Gl and G’Z 
arrest. Either they cause damage to the cell that can be 
detected by either a Cl or G2 checkpoint, or they inhibit 
targets that are essential to both phases. 
One major class of compounds consists of the DNA dam- 
aging agents (Fig. 5). Surprisingly, at low concentrations, 
they do not cause S-phase arrest. Instead, cells in S phase 
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Figure 6 
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Gl- and GP-arrest agents. (a) Agents affecting the cell-cycle engine by inhibition of either synthesis (cycloheximide) degradation (lactacystin) or 
activitation (olomoucine) of cell-cycle components. (b) PKC modulators. (c) Agents inhibiting other processes. 
treated with DNA-damaging agents progress to a G2 
arrest. Clinically used synthetic DNA alkylating agents 
include the nitrogen mustards (e.g., cyclophosphamide), 
alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., lomus- 
tine), and triazenes (e.g., dicarbazine) [56]. Recently, 
natural products that damage DNA have been the focus of 
great interest to chemists, both synthetically, because of 
their complex architecture and functionality, and mecha- 
nistically. These compounds include neocarzinostatin 
[60,61] mitomycin C, and bleomycin [6’2]. The mecha- 
nisms of cell-cycle arrest by DNA-damaging agents can be 
complicated. The DNA-damaging agent cisplatin illus- 
trates this point. Cisplatin was originally thought to act 
simply by crosslinking DNA via nucleophilic displace- 
ment of its chlorides by the N7 of guanines. Recent work 
however, demonstrates that this cisplatin-DNA adduct 
binds certain nuclear proteins, such as SRY (the human 
testis-determining protein) and hMSH2. This 
protein-ligand complex may shield the DNA damage 
from repair mechanisms [63-651. 
These compounds have facilitated an understanding of the 
cellular response to DNA damage. It now appears that it is 
not the DNA damage inflicted by these compounds that 
directly causes arrest. Instead, in mammalian cells, the 
DNA damage causes arrest at a checkpoint by activating 
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~53 by an unknown mechanism, leading to the trans- 
criptional activation of the gene encoding ~‘21 (a Cdk 
inhibitor, see above) [66,67]. In budding yeast, two rad 
mutants (see above) that are defective at this checkpoint 
are insensitive to the DNA-damaging agent bleomycin [68]. 
These results demonstrate that DNA-damaging agents 
cause arrest by activating a DNA-damage checkpoint in the 
cell cycle, resulting in inhibition of cell-cycle progression 
(through ~‘21 in mammalian cells) and activation of the 
DNA-repair machinery. Only if the damage is not repaired 
will apoptosis be induced. Thus, DNA-damaged cells are 
either repaired or eliminated. 
A second class of Gl- and G&arrest agents includes 
inhibitors of protein synthesis or degradation, which arrest 
the cell cycle in different phases, depending on the time 
of treatment (Fig. 6a); these arrests may be a result of an 
inhibition of the synthesis or degradation of many pro- 
teins. For example, cycloheximide [69] blocks the transla- 
tion of cyclins [70,71], whereas lactacystin inhibits protein 
degradation by the 26s proteasome by binding to its 
X/MB1 subunit [72], a close homolog of the LMP7 
subunit encoded by the major histocompatibility complex. 
This binding blocks the degradation of proteins that nor- 
mally prevent neurite outgrowth [73], and presumably of 
cyclin, as it is degraded by the proteasome. 
The aminopurines are also thought to mediate their effects 
by modulating Cdk-cyclin activity, but in a more direct 
manner than affecting protein levels (Fig. 6a). Because the 
aminopurines are ATP analogs, they can serve as nonselec- 
tive protein-kinase inhibitors. The analog olomoucine, 
however, is selective for the Cdks. It competitively inhibits 
ATP binding to the kinase domain of the Cd&cyclin B, 
CdkZ-cyclin A, and CdkZ-cyclin E complexes [74]. Gl 
and G2 arrest probably occur by the inhibition of 
CdkZ-cyclin E and Cdc%cyclin B, respectively. 
Inhibitors of other protein kinases also cause arrest in Gl 
and G2 (Fig. 6b). Their mechanisms of action are much less 
clear, however, due in part to a poorer understanding of the 
role of these kinases in the cell cycle. Staurosporine and 
K25’2a are examples of protein kinase C (PKC) inhibitors 
that cause Gl arrest at low concentrations (20 nM) and GZ 
arrest at higher concentrations (ZOO nM) [75-771. These 
compounds are not, however, selective for PKC, as they 
also inhibit Cd&-cyclin B, CdcZ-cyclin A, and CdkZ-cyclin 
A complexes in vitro [78]. In contrast, the structurally 
related UCN-01 [79] and quercetin [80] are much more 
selective PKC inhibitors, which cause predominantly Gl 
arrest. Finally, a third type of PKC inhibitor, characterized 
by the structurally unrelated ilmofosine, a thioether phos- 
pholipid that specifically inhibits PKC by competitive 
binding to the phospholipid site, causes G2 arrest, indi- 
rectly suppressing CdcZ-cyclin B activity by affecting levels 
of cyclin B [81]. Clearly, the more specific inhibitors UCN- 
1, quercetin, and ilmofosine suggest that PKC has a role in 
both Gl and G2 progression. They also demonstrate the 
diversity of PKC and its many isozymes. In yeast, it has 
been shown that a conventional form of the kinase, cPKC, 
is essential in the G’Z to M progression [82], and in mouse 
fibroblasts a novel form, nPKC, is essential in the Gl to S 
progression [83]. Thus, the differences in the phase of cell- 
cycle arrest observed with the various PKC inhibitors may 
reflect their specificities for the various PKC isoforms. The 
complexity of PKC is demonstrated by the varying effects 
of numerous other PKC modulators such as bryostatin [84], 
teleocidin [85], and perhaps resinferitoxin [86] on cellular 
proliferation. A promising area of research combines the use 
of natural products as templates for combinatorial chem- 
istry and screens capable of identifying variants that inhibit 
specific kinases. 
The use of other natural products that cause cell-cycle arrest 
has led to the identification of additional conditions required 
for cell-cycle progression (Fig. 6~). Histone deacetylation 
seems to be critical to both Gl and G’2, since its inhibition 
by n-butyrate, trichostatin, or trapoxin [87] can results in 
arrest in either of these phases. The relationship between 
hyperacetylation of core histones and cell-cycle regulation 
however, remains to be elucidated. The recent discovery 
and cloning of the target of trapoxin and trichostatin, human 
histone deacetylase-1 (HDl), promises to expand this excit- 
ing area of research [88]. Further, inhibition of polyamine 
synthesis by o-methyl ornithine (an inhibitor of L-ornithine 
decarboxylase in the biosynthesis of putrescine) or methyl- 
glyoxal bis-guanylhydrazone (an inhibitor of S-adenosyl 
methionine decarboxylase in the biosynthesis of spermidine 
and spermine) blocks DNA synthesis and cell division [89]. 
Polyamines may stabilize DNA folding [90] or activate DNA 
polymerase [91]. Lastly, growing interest in sphingolipids as 
signaling molecules for cellular proliferation has resulted 
in the identification of a glucosylceramide synthase inhibi- 
tor t~reo-l-phenyl-2-decanoylamino-3-morpholino-l-propanol 
(PDMP) [92]. PDMP blocks the Gl/S and GZ/M transitions 
by effecting decreases in CdQ and CdkZ activity. Although 
the mechanism of this decrease remains a mystery, sphingo- 
lipids have been implicated in cellular proliferation and dif- 
ferentiation, DNA synthesis [93], transcription [94], and 
apoptosis [95]. The natural product myriocin may help in 
understanding how these sphingolipid-dependent signaling 
pathways tie in with cell-cycle progression. Myriocin has 
been reported to inhibit a serine palmitoyltransferase activ- 
ity that is required for the first step of sphingolipid biosyn- 
thesis [96,97]. Thus the cell cycle, particularly the critical 
Gl/S and GZ/M transitions, requires a multitude of pro- 
tein mediators, and disruption of just a single one of these 
activities is sufficient to interrupt its progression. 
G2-phase-specific arrest agents 
Two major classes of G&specific, cell-cycle arrest agents 
are the inhibitors of topoisomerase II (Fig. 7a) and 
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serinelthreonine phosphatases (Fig. 7b). The tyrosine 
kinase inhibitors genistein [98] and herbimycin [99] (Fig. 
7c) comprise a recently discovered third class, but their 
mechanisms of action are not yet understood. 
The anthracyclines doxorubicin and daunomycin, and 
the podophyllotoxins etoposide and tenoposide, were 
originally thought to act simply by cleaving DNA via 
semiquinone radicals (Fig. 7). The observation that some 
doxorubicin-resistant tumors contain undetectable or 
very low topoisomerase II activity [loo], however, sug- 
gests that these molecules may require topoisomerase II 
[loll to arrest cells. Some evidence suggests that arrest 
occurs at concentrations sufficiently low that no DNA 
cleavage is observed, but that topoisomerase II activity is 
inhibited. Alternatively, topoisomerase II may potentiate 
the ability of the anthracyclines to cleave DNA, thus 
lowering the necessary effective concentration. Confir- 
mation that inhibition of topoisomerase II may be suffi- 
cient to effect arrest came from studies done with a 
different topoisomerase II inhibitor, ICRF-193 [10’2]. 
ICRF-193 inhibits topoisomerase II in a DNA-indepen- 
dent manner, without direct damage to DNA. This com- 
pound, like doxorubicin and daunomycin, also causes G2 
Figure 7 
arrest in mammalian cells, indicating that prior to entry 
into mitosis, a checkpoint monitors successful chromoso- 
ma1 condensation and proper topology resulting from 
topoisomerase II activity, independent of DNA-damage 
and -repair pathways [24]. 
Okadaic acid and calyculin A are potent protein phos- 
phatase (PP) inhibitors, selective for the serine/threonine 
phosphatases PPl and PPZA. At low concentrations 
(20 nM), they cause a GZ/M block, prior to activation of 
Cd&-cyclin B complexes [103]. The mechanism of this 
arrest may involve the PPZA-like activities that regulate 
Cd&?5 phosphatase and wee1 kinase, which in turn regu- 
late the phosphorylation status of Cd&. Sodium orthovana- 
date is an inhibitor of tyrosine phosphatases. It also causes a 
G2 block, perhaps by inhibiting Cd&?5 dephosphorylation 
and activation of Cd&-cyclin B complexes [104]. 
M-phase-specific arrest agents 
Most of the mitotic arrest agents (Fig. 8) seem to act by 
interfering with cytoskeletal organization, predominantly 
affecting the microtubules required for spindle formation 
and chromosome segregation, although some agents inter- 
fere with actin, which is required for cytokinesis. (A recent 
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G2-specific arrest agents. (a) Topoisomerase II inhibitors. (b) Phosphatase 1 and 2A inhibitors. (c) Tyrosine kinase inhibitors. 
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exception is ilimaquinone, which causes a complete 
breakdown of the Golgi and thus inhibition of secretion, 
as well as mitotic arrest by an unknown mechanism [ 1051.) 
The mechanism of action of cytochalasins is seemingly 
simple - at the end of mitosis they inhibit cytokinesis by 
binding to actin and preventing its polymerization [106] 
- but the end effect on the cell cycle is actually quite 
complicated. While the cytochalasins act during mitosis to 
prevent actin polymerization, they do not cause M-phase 
arrest but allow the cell to progress into the next Gl 
phase. Release from the block within a certain time frame 
allows cytokinesis to occur in Gl [107]. Thus, it appears 
that mitosis and cytokinesis are two distinct and somewhat 
independent events. 
By far the largest class of mitotic arrest agents affect 
microtubule formation (Fig. 8). Microtubules and their 
attachment to the kinetochore have a critical role in cell 
division, since unattached kinetochores can prevent exit 
from mitosis by generating a checkpoint signal that 
inhibits the cell-cycle machinery [26]. The spindle is com- 
posed of microtubules, and the mechanics of microtubule 
elongation and shortening control mitotic spindle forma- 
tion. Because the dynamic behavior of microtubules is 
critical for proper chromosome alignment and segregation, 
it is not surprising that compounds that exaggerate either 
the stability or instability of microtubules will disrupt their 
mechanical function. The majority of these compounds 
are destabilizing agents. 
Tubulin exists as a dimer consisting of 01 and B subunits. 
Microtubule-destabilizing agents tend to bind the free 
dimer, preventing polymerization. Two major binding sites 
have been identified for these compounds. Colchicine 
binds to a single site on the dimer with pseudo-irreversible 
kinetics, suggesting that conformational changes occur in 
both the ligand and tubulin dimer. By photoaffinity label- 
ing, the colchicine binding site has been localized to two 
small amino-terminal and carboxy-terminal regions on 
B-tubulin that lie near B-tubulin’s point of interaction with 
cx-tubulin [108]. Other microtubule-destabilizing agents, 
including podophyllotoxin [ 1091 and nocodazole [ 1 lo], 
bind at sites that overlap with the colchicine site, but in a 
reversible manner. The colchicine site is distinct from the 
vinca alkaloid binding site. Vinblastine and vincristine 
[ 11 l] bind at two high affinity sites on each tubulin dimer 
resulting in stabilization of the c$ heterodimer but desta- 
bilization of microtubule polymers. Whereas the vinca 
alkaloids bind in a reversible manner, maytansine binds 
covalently at the vinca alkaloid site, alkylating tubulin 
with its epoxide group [112]. Halichondrin [113], ustiloxin 
A [114], and spongistatin [115] also bind tubulin at the 
vinca alkaloid site. The binding site on tubulin of estra- 
mustine has not been determined [116]. Interestingly, 
substoichiometric amounts of each of these compounds are 
sufficient to inhibit completely microtubule assembly 
[ 1171. This phenomenon has led to the proposal that 
further polymerization is inhibited by the ‘capping’ of the 
growing ‘plus’ end of a microtubule by a tubulin-drug 
complex; meanwhile, the dynamic nature of microtubules 
and the difference in polymerization rates at the two ends 
permits continued depolymerization at the ‘minus’ end, 
resulting in net disassembly. 
In contrast to the destabilizing agents, taxol [118] pro- 
motes the stabilization of microtubules, both in vitro and 
in v&o, presumably causing mitotic arrest by preventing 
proper assembly of the mitotic spindle [119] or by reduc- 
ing chromosome oscillations [120]. Structures of tax01 
bound to microtubules have been reported using electron 
diffraction [121] X-ray scattering [122] and electron 
microscopy [123]. Photoaffinity labeling of tubulin by a 
taxol analog localizes the taxol-binding site to the amino 
terminus of B-tubulin [124]. The marine natural product 
discodermolide also stabilizes microtubules [ 1251 by 
binding directly to them with a higher affinity than is 
found for taxol binding [126]. As with taxol, binding was 
found to be stoichiometric with tubulin dimers. Using trit- 
iated taxol and discodermolide, it was found that the 
binding of these two natural products is mutually exclu- 
sive, suggesting a possible common binding site despite 
the lack of any obvious structural similarities. Epothilone 
is a competitive inhibitor of taxol, which also stabilizes 
microtubules and shows no obvious structural similarities 
to either taxol or discodermolide [127]. Rhazanilam has 
been reported both as a stabilizing and destabilizing agent 
towards microtubules [ 1281. 
Whereas the agents discussed above interfere with micro- 
tubule stability by direct interactions with tubulin, one 
natural product, griseofulvin, may have an indirect effect. 
Griseofulvin was originally reported as a mitotic arrest 
agent that did not alter microtubule stability [129]. Later 
work, however, revealed that the compound interferes 
with microtubule polymerization without binding to puri- 
fied microtubules [ 1301. This finding raises the possibility 
that griseofulvin may have an indirect effect on micro- 
tubules, possibly mediated by microtubule-associated pro- 
teins (MAPS), which regulate microtubule polymerization. 
Thus, whether they function directly through association 
or indirectly through MAPS, it is clear that compounds 
that disrupt the normal balance of polymerization and 
depolymerization of microtubules cause mitotic arrest. 
Natural products that activate programmed cell death 
Prolonged disruption of the cell cycle results ultimately in 
death that has been proposed to occur via programmed cell 
death (apoptosis). In other words, if the cell is not viable, it 
commits suicide. Many small-molecule, cell-cycle arrest 
agents such as aphidicolin [131], vincristine [132], taxol 
[133], mitomycin C and staurosporine [134] cause apopto- 
sis by either p53-dependent or -independent pathways 
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[ 1351. In addition to activating a checkpoint arrest in DNA- 
damaged cells, p53 also seems to be responsible for indu- 
cing death if repair fails [136]. Clearly, studying the 
mechanisms of many of these natural product inhibitors 
will help to elucidate the regulation of the suicidal process. 
Understanding their relationships to apoptosis may result 
in the development of more efficacious chemotherapeutic 
approaches to inducing apoptosis in cancer cells. 
Natural products to probe checkpoint-signaling pathways 
Checkpoint signaling is an important yet poorly under- 
stood area of signaling research. Rapamycin (see above) is 
one important tool that is helping to illuminate these fasci- 
nating processes. Human FRAP and the yeast TOR pro- 
teins, the targets of FKBPlZ-rapamycin, appear to act as 
Gl sensors. One hypothesis is that these proteins monitor 
cell size and/or the existence of external nutrients by mon- 
itoring the state of messenger RNA molecules. These pro- 
teins are homologs of the yeast Mecl protein (see above), 
which is a sensor of the status of DNA molecules, and are 
members of a newly identified family of proteins, the 
phosphatidylinositol kinase (PIK)-related kinases, that 
appear to be critical to several checkpoint-signaling path- 
ways that monitor the status of polynucleotides [137]. The 
mutation of one member of this gene family is responsible 
for the disease ATM (ataxia telangiectasia), which seems 
to be caused by an error in a signal to the tumor suppressor 
and checkpoint protein p53 [17,138]. 
Natural products to control the cell cycle 
The ability to control the timing of arrest facilitates efforts 
to understand cell-cycle regulation, and the extensive 
collection of specific arrest agents provides the tools 
necessary for this control. The definition of the arrest point 
within the cycle is a necessary prerequisite before a natural 
product can be used in this manner. Analysis of cyclin 
expression has proven to be more precise than the determi- 
nation of the DNA content of cells by flow cytometry alone 
Figure 9 
(2N for Gl diploid cells, 4N for GZ or M diploid cells). For 
example, in synchronized cells that have been treated with 
a Gl arrest agent, the appearance of cyclin D, but not 
cyclin E, indicates that the block is in early to mid Gl. In 
contrast, appearance of both cyclins indicates a late Gl 
block. Given the caveat of cell-line dependence, this type 
of analysis can be used in Gl by examining cyclin D and E 
expression [76,139], and in G2 by examining cyclin A and 
B expression [140]. Although the majority of compounds 
have not been analyzed at this level of detail, Figure 9 
summarizes the results obtained for some compounds. 
These molecules can be used to synchronize an entire 
population of cells at many different and now characterized 
stages of the cell cycle, as the blocks are reversible. 
Washing the cells with media free of the blocking agent 
allows the cells to continue through the cycle, beginning 
precisely at the stage of the reversible block. 
Orphan ligands - new probes of the cell cycle 
A cornucopia of small molecules exist that have potential 
as tools for studying the cell cycle. Some of them show 
cell-cycle-specific effects, yet their mechanisms of inhibi- 
tion are unknown. Even more of them have gone unde- 
tected within the pool of known natural products as they 
have not yet been examined for this activity. We have 
depicted some interesting candidates in Figure 10, chosen 
primarily based on the criterion of provocative or 
unknown biological activity. These compounds include 
deoxyspergualin [141], depudecin [142], didemnins (for 
which two protein receptors have been identified, yet for 
which a clear mechanism of cell-cycle arrest has not 
emerged) [143-1451, leptolstatin [146], palau’amine 11471, 
and diazonamide A [148]. These molecules are but a few 
representatives of an important resource from which 
invaluable tools for dissecting the cell cycle may be found. 
Natural products have been described as ‘genetically- 
encoded libraries of peptidomimetic, small molecule 
Relative timing of arrest by different cell-cycle 
arrest agents. 
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ligands’ (J. Clardy, personal communication), and these 
naturally-occurring compounds have been central to the 
illumination of many molecular details of the cell cycle. 
The recent emergence of combinatorial chemistry may be 
the harbinger of yet another exciting merging of the fields 
of organic chemistry and cell biology. Combinatorial syn- 
thesis is a laboratory emulation of nature’s generation of 
diversity, and this ability to generate tremendous numbers 
of diverse molecules gives this method the potential to be 
a very powerful tool for the next generation of investigators 
of the cell cycle. 
References 
1. Brown, E.J., Beal, P.A., Keith, C.T., Chen, J., Shin, T.B. & Schreiber, 
S.L. (1995). Control of p70 s6 kinase by kinase activity of FRAP in 
viva. Nature 377, 441-446. 
2. Belshaw, P.J., Ho, S.N., Crabtree, G.R. & Schreiber, S.L. (1996). 
Controlling protein association and subcellular localization with a 
synthetic ligand that induces heterodimerization of proteins. Proc. 
Nat/. Acad. Sci USA 93,4604-4607. 
3. Combs, A.P., Kapoor, T.M., Feng, S., Chen, J.K., Daude-Snow, L.F. & 
Schreiber, S.L. (1996). Protein structure-based design of 
combinatorial libraries: discovery of non-peptide binding elements to 
Src SH3 domain. J. Am. Chem. Sot. 118, 287-288. 
4. Murray, A. & Hunt, T. (1993). The Cell Cycle. W. H. Freeman, New 
York. 
5. Williams, G.T. & Smith, CA. (1993). Molecular regulation of 
apoptosis: genetic controls on cell death. Cell 74, 777-779. 
6. Wyllie, A.H., Kerr, J.F. & Currie, A.R. (1980). Cell death: the 
significance of apoptosis. Int Rev. Cytol. 68, 251-306. 
7. Hunter, T. (1993). Braking the cycle. Cell 75, 839-841. 
8. McKinney, J.D. & Heintz, N. (1991). Transcriptional regulation in the 
eukaryotic cell cycle. Trends B/o&em. Sci. 16, 430-435. 
9. Joshi, H.C., Palacios, M.J., McNamara, L. & Cleveland, D.W. (1992). 
Gamma-tubulin is a centrosomal protein required for cell cycle 
dependent microtubule nucleation. Nature 356, 80-83. 
10. Doheny, K.F., Sorger, P.K., Hyman, A.A., Tugendreich, S., Spencer, F. 
& Hieter, P. (1993). Identification of essential components of the S. 
cerevisiae kinetochore. Cell 73, 761-774. 
11. Murray, A.W. (1992). Creative blocks: cell-cycle checkpoints and 
feedback controls. Nature 359, 599-604. 
12. Hartwell, L.H. & Weiner-t, T.A. (1989). Checkpoints: controls that 
ensure the order of cell cycle events. Science 246, 629-634. 
13. Johnston, G.C., Pringle, J.R. & Hartwell, L.H. (1977). Coordination of 
growth with cell division in the yeast Saccharomyces cerevisiae. hp. 
Cell. Res. 105, 79-98. 
14. Weinert, T.A. & Hartwell, L.H. (1988). The RAD9 gene controls the 
Review Natural product inhibitors of the cell cycle Hung et a/. 637 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
cell cycle response to DNA damage in Saccharomyces cerevisiae. 
Science 241,317-322. 
Shinohara, A., Ogawa, H. & Ogawa, T. (1992). Rad51 protein involved 
in repair and recombination in S. cerevisiae is a RecA-like protein. Cell 
69,457-470. 
Chen, P.L., Chen, Y.M., Bookstein, R. & Lee, W.H. (1990). Genetic 
mechanisms of tumor suppression by the human p53 gene. Science 
250,1576-i 580. 
Vogelstein, B. & Kinzler, K.W. (1992). p53 function and dysfunction. 
Cell70, 523-526. 
Nasmyth, K. & Hunt, T. (1993). Cell cycle. Dams and sluices. Nature 
366,634-635. 
Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. & Elledge, S.J. 
(1993). The p21 Cdk-interacting protein Cipl is a potent inhibitor of 
Gl cyclin-dependent kinases. Cell 75, 805-816. 
Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R. & Beach, 
D. (1993). ~21 is a universal inhibitor of cyclin kinases. Nature 366, 
701-704. 
Polyak, K., et a/., & Massague, J. (1994). Cloning of p27Kip1, a cyclin- 
dependent kinase inhibitor and a potential mediator of extracellular 
antimitogenic signals. Cell 78, 59-66. 
Toyoshima, H. & Hunter, T. (1994). ~27, a novel inhibitor of Gl cyclin- 
Cdk protein kinase activity, is related to ~21. Cell 78, 67-74. 
Dasso, M. & Newport, J.W. (1990). Completion of DNA replication is 
monitored by a feedback system that controls the initiation of mitosis 
in vitro: studies in Xenopus. Cell 61, 81 I-823. 
Dowries, C.S., Clarke, D.J., Mullinger, A.M., Gimenez Abian, J.F., 
Creighton, A.M. & Johnson, R.T. (1994). A topoisomerase II- 
dependent G2 cycle checkpoint in mammalian cells. Nature 372, 
467-470. 
Heck, M.M., Hittelman, W.N. & Earnshaw, WC. (1988). Differential 
expression of DNA topoisomerases I and II during the eukaryotic cell 
cycle. froc Nat/ Acad Sci USA 85, 1086-I 090. 
Rieder, C.L., Cole, R.W., Khodjakov, A. & Sluder, G. (1995). The 
checkpoint delaying anaphase in response to chromosome 
monoorientation is mediated by an inhibitory signal produced by 
unattached kinetochores. J. Cell Biol. 130, 941-948. 
Ullrich, A. & Schlessinger, J. (1990). Signal transduction by receptors 
with tyrosine kinase activity. Cell 61, 203-212. 
Cantley, L.C., et a/., & Soltoff, S. (1991). Oncogenes and signal 
transduction. Cell 64, 281-302. 
Liu, J., Farmer, J.D., Jr., Lane, W.S., Friedman, J., Weissman, I. & 
Schreiber, S.L. (1991). Calcineurin is a common target of 
cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 
807-815. 
Schreiber, S.L. (1992). Immunophilin-sensitive protein phosphatase 
action in cell signaling pathways. Cell 70, 365-368. 
Kwon, H.J., Yoshida, M., Fukui, Y., Horinouchi, S. & Beppu, T. (1992). 
Potent and specific inhibition of p60y-src protein kinase both in viva 
and in vitro by radicicol. Cancer Res. 52, 6926-6930. 
Sonoda, T., Osada, H., Uramoto, M., Uzawa, J. & Isono, K. (1989). 
Epiderstatin, a new inhibitor of the mitogenic activity induced by 
epidermal growth factor. II. Structure elucidation. J. Antibiot. (Tokyo) 
42,1607-l 609. 
Osada, H., Koshino, H., Isono, K., Takahashi, H. & Kawanishi, G. 
(1991). Reveromycin A, a new antibiotic which inhibits the mitogenic 
activity of epidermal growth factor. J. Antibiot. (Tokyo) 44, 259-261. 
Brown, E.J., et al., & Schreiber, S.L. (1994). A mammalian protein 
targeted by Gl -arresting rapamycin-receptor complex. Nature 369, 
756-758. 
Sabatini, D.M., Erdjument Bromage, H., Lui, M., Tempst, P. & Snyder, 
S.H. (1994). RAFT1 : a mammalian protein that binds to FKBPI 2 in a 
rapamycin-dependent fashion and is homologous to yeast TORs. Cell 
78,35-43. 
Kunz, J., Henriquez, R., Schneider, U., Deuter Reinhard, M., Movva, 
N.R. & Hall, M.N. (1993). Target of rapamycin in yeast, TOR2, is an 
essential phosphatidylinositol kinase homolog required for Gl 
progression. Cell 73, 585-596. 
Haghighat, A., Mader, S., Pause, A. & Sonenberg, N. (1995). 
Repression of cap-dependent translation by 4E-binding protein 1: 
competition with ~220 for binding to eukaryotic initiation factor-4E. 
EM50 J. 14,5701-5709. 
Cheatham, B., Vlahos, C.J., Cheatham, L., Wang, L., Blenis, J. & Kahn, 
C.R. (1994). Phosphatidylinositol 3-kinase activation is required for 
insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose 
transporter translocation. MO/. Cell. Biol. 14, 4902-4911. 
Chung, J., Grammer, T.C., Lemon, K.P., Kazlauskas, A. & Blenis, J. 
40. 
41. 
42. 
43. 
44. 
45. 
46. 
47. 
48. 
49. 
50. 
51. 
52. 
53. 
54. 
55. 
56. 
57. 
58. 
59. 
60. 
61. 
62. 
83. 
(1994). PDGF- and insulin-dependent pp7Osek activation mediated by 
phosphatidylinositol-3-OH kinase. Nature 370, 71-75. 
Yano, H., et al., & Matsuda, Y. (1993). Inhibition of histamine secretion 
by wortmannin through the blockade of phosphatidylinositol 3-kinase 
in RBL-2H3 cells. J. &of. Chem. 268, 25846-25856. 
Calve, V., Crews, CM., Vik, T.A. & Bierer, B.E. (1992). lnterleukin 2 
stimulation of p70 S6 kinase activity is inhibited by the 
immunosuppressant rapamycin. Proc. Nat/. Acad. Sci. USA 89, 
7571-7575. 
Kuo, C.J., Chung, J., Fiorentino, D.F., Flanagan, W.M., Blenis, J. & 
Crabtree, G.R. (1992). Rapamycin selectively inhibits interleukin-2 
activation of p70 S6 kinase. Nature 358, 70-73. 
Chung, J., Kuo, C.J., Crabtree, G.R. & Blenis, J. (1992). 
Rapamycin-FKBP specifically blocks growth-dependent activation of 
and signaling by the 70-kD S6 protein kinases. Cell 69, 1227-i 236. 
Quesney-Huneeus, V., Galick, H.A., Siperstein, M.D., Erickson, SK., 
Spencer, T.A. & Nelson, J.A. (1983). The dual role of mevalonate in 
the cell cycle. J. No/. Chem. 258, 378-385. 
Quesney Huneeus, V., Wiley, M.H. & Siperstein, M.D. (1979). 
Essential role for mevalonate synthesis in DNA replication. Proc. Nat/. 
Acad. Sci USA 76,5056-5060. 
Dawson. M.J. et a/.. & Haves, M.V. (1992). The squalestatins. novel 
inhibitors of squalene synthase produced by a species of Phoma. I. 
Taxonomy, fermentation, isolation, physico-chemical properties and 
biological activity. J. Antibiot. (Tokyo) 45, 639-647. 
Langan, T.J. & Volpe, J.J. (1987). Cell-cycle-specific requirement for 
mevalonate, but not for cholesterol, for DNA synthesis in glial primary 
cultures. J. Neurochem. 49, 513-521. 
Langan, T.J. & Slater, M.C. (1991). lsoprenoids and astroglial cell 
cycling: diminished mevalonate availability and inhibition of dolichol- 
linked glvcoprotein synthesis arrest cycling through distinct 
mechanisms. J. Cell.~Physiol. 149, 284-252. - 
Ishii, S. & Volpe, J.J. (1987). Dolichol-linked qlvcoprotein svnthesis in 
Gl is necessary for DNA synthesis in synchronized prima& cultures of 
cerebral glia. J. Neurochem. 49, 1606-I 612. 
Lennarz, W.J. (1985). Regulation of glycoprotein synthesis during 
development of the sea urchin embryo. Dev. Biol. 3, 59-79. 
Larsson, 0. & Zetterberg, A. (1986). Effects of 25-hydroxycholesterol, 
cholesterol, and isoprenoid derivatives on the Gi progression in 
Swiss 3T3 cells. J. Cell. Physiol. 129, 94-l 02. 
Doyle, J.W. & Kandutsch, A.A. (1988). Requirement for mevalonate in 
cycling cells: quantitative and temporal aspects. J. Cell. Physiol. 137, 
133-l 40. 
Huneeus, V.G., Wiley, M.H. & Siperstein, M. D. (1980). 
lsopentenyladenine as a mediator of mevalonate-regulated DNA 
replication. froc. Nat/. Acad. Sci. USA 77, 5842-5846. 
Kohl, N.E., et a/., & Gibbs, J.B. (1993). Selective inhibition of ras- 
dependent transformation by a farnesyltransferase inhibitor. Science 
260, 1934-l 937. 
James, G.L., et a/., & Marsters, J.C., Jr. (1993). Benzodiazepine 
peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. 
Science 260, 1937-l 942. 
Calabresi, P. & Parks, R.E. (1985) Chemotherapy of neoplastic 
diseases. In Goodman and Gilman’s The Pharmacological Basis of 
Therapeutics. (Hardman, J.G.G., Gilman, A. & Limbird, L.L., eds), pp 
1240-I 306, MacMillan, New York. 
Schlegel, R. & Pardee, A.B. (1986). Caffeine-induced uncoupling of 
mitosis from the completion of DNA replication in mammalian cells. 
Science 232, 1264-l 266. 
Raff, J.W. & Glover, D.M. (1988). Nuclear and cytoplasmic mitotic 
cycles continue in Drosophila embryos in which DNA synthesis is 
inhibited with aphidicolin. J. Cell. Biol. 107, 2009-2019. 
Gilbert, D.M., Neilson, A., Miyazawa, H., DePamphilis, M.L. & Burhans, 
W.C. (1995). Mimosine arrests DNA synthesis at replication forks by 
inhibiting deoxyribonucleotide metabolism. J. Biol. Chem. 270, 
9597-9606. 
Nicolaou, K.C. & Dai, W.M. (1991). Chemistry and biology of 
enediyne-cytostatic antibiotics. Angew. Chem. Int Ed. Engl. 30, 
1387-l 416. 
Goldberg, I.H. (1991). Mechanism of neocarzinostatin action: role of 
DNA microstructure in determination of chemistry of bistranded 
oxidative damage. Act. Chem. Res. 24, 191-I 98. 
Stubbe, J. & Kozarich, J.W. (1987). Mechanisms of bleomycin-induced 
DNA degradation. Chem. Rev. 87, 1107-l 136. 
Huang, J.C., Zamble, D.B., Reardon, J.T., Lippard, S.J. & Sancar, A. 
(1994). HMG-domain proteins specificallv inhibit the repair of the 
major DNA adduct of the anticancer drug cisplatin by human excision 
638 Chemistry & Biology 1996, Vol3 No 8 
64. 
65. 
66. 
67. 
68. 
69. 
70. 
71. 
72. 
73. 
74. 
75. 
76. 
77. 
78. 
79. 
80. 
81. 
82. 
83. 
84. 
85. 
86. 
87. 
88. 
nuclease. Proc. Nat/. Acad. Sci. USA 91, 10394-l 0398. 
Takahara, P.M., Rosenzweig, A.C., Frederick, CA. & Lippard, S.J. 
(1995). Crystal structure of double-stranded DNA containing the 
major adduct of the anticancer drug cisplatin. Nature 377, 649-652. 
Mello, J.A., Acharya, S., Fishel, R. & Essigmann, J.M. (1996). The 
mismatch-reoair orotein hMSH2 binds selectivelv to DNA adducts of 
the anticancer drug cisplatin. Chemistry & Bio/o$y 3, 579-589. 
Canman. C.E.. Wolff, A.C.. Chen. C.Y.. Fornace. A.J.. Jr. & Kastan. 
M.B. (1994). The p53-dependent Gl cell cycle checkpoint pathway 
and ataxia-telangiectasia. Cancer Res. 54, 5054-5058. 
Nelson, W.G. & Kastan, M.B. (1994). DNA strand breaks: the DNA 
template alterations that trigger p53-dependent DNA damage 
response pathways. Mol. Cell. Biol. 14, 1815-l 823. 
Belenguer, P., Oustrin, M.L., Tiraby, G. & Ducommun, B. (1995). 
Effects of phleomycin-induced DNA damage on the fission yeast 
Schizosaccharomyces pombe cell cycle. Yeast 11, 225-231. 
Medrano, E.E. & Pardee, A.B. (1980). Prevalent deficiency in tumor 
cells of cycloheximide-induced cycle arrest. Proc. Nat/. Acad. Sci. 
USA 7774123-4126. 
Hershko, A., Ganoth, D., Pehrson, J., Palazzo, R.E. & Cohen, L.H. 
(1991). Methylated ubiquitin inhibits cyclin degradation in clam 
embryo extracts. J. Biol. Chem. 266, 16376-I 6379. 
Glotzer, M., Murray, A.W. & Kirschner, M.W. (1991). Cyclin is 
degraded by the ubiquitin pathway. Nature 349, 132-l 38. 
Fenteanv, G., Standaert, R.F., Lane, W.S.. Choi. S.. Corev. E.J. & 
Schreiber, S.L. (I 995). inhibition of proteasome activities and subunit- 
specific amino-terminal threonine modification by lactacystin. Science 
268,726-731. 
Fenteany, G., Standaert, R.F., Reichard, G.A., Corey, E.J. & Schreiber, 
S.L. (1994). A 8-lactone related to lactacystin induces neurite 
outgrowth in a neuroblastoma cell line and inhibits cell cycle 
progression in an osteosarcoma cell line. Proc. Nat/. Acad. Sci. USA 
91,3358-3362. 
Vesely, J., et a/., & Meijer, L. (1994). Inhibition of cyclin-dependent 
kinases by purine analogues. Eur. J. Biochem. 224, 771-786. 
Abe, K., Yoshida, M., Usui, T., Horinouchi, S. & Beppu, T. (1991). 
Highly synchronous culture of fibroblasts from G2 block caused by 
staurosporine, a potent inhibitor of protein kinases. Exp. Cell. Res. 
192,122-127. 
Lin, Y., Chrest, F.J. & Gabrielson, E.W. (1992). Reversible Gl arrest of 
a human lung epithelial cell line by staurosporine. 1. Cell. Physiol. 152, 
646-653. 
Gong, J., Traganos, F. & Darzynkiewicz, Z. (1994). Staurosporine 
blocks cell progression through Gl between the cvclin D and cvclin E 
restriction poi&. Cancer Re; 54, 3136-3139. . 
Gadbois, D.M., Hamaguchi, J.R., Swank, R.A. & Bradbury, E.M. 
(1992). Staurosporine is a potent inhibitor of p34cdc* and p34cdc2-like 
kinases. Biochem. Biophvs. Res. Commun. 184,80-85. 
Seynaeve, CM., et a/.,‘& Worland, P.J. (1993). Cell-cycle arrest and 
growth inhibition bv the protein kinase antaoonist UCN-01 in human 
breast carcinoma cells. Cancer Res. 53, 2081-2086. 
Yoshida, M., Yamamoto, M. & Nikaido, T. (1992). Quercetin arrests 
human leukemic T cells in late Gl phase of the cell cycle. Cancer 
Res.52,6676-5681. 
Hofmann, J., et a/., & Grunicke, H. (1994). The protein kinase C 
inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and 
suppresses CDC2 kinase activation through a mechanism different 
from that of DNA damaging agents. Biochem. Biophys. Res. 
Commun. 199,937-943. 
Levin, D.E., Fields, F.O., Kunisawa, R., Bishop, J.M. & Thorner, J. 
(1990). A candidate protein kinase C gene, PKCl , is required for the 
S. cerevisiae cell cycle. Cell 62, 213-224. 
Ohno, S., et aL, & Suzuki, K. (1991). Structural and functional 
diversities of a family of signal transducing protein kinases, protein 
kinase C family; two distinct classes of PKC, conventional cPKC and 
novel nPKC. Adv. Enzyme Regul. 31, 287-303. 
Pettit, G.R. (1991). The bryostatins. Prog. Chem. Org. Nat. Prod. 57, 
153-195. 
Fujiki, H. & Sugimura, T. (1987). New classes of tumor promoters: 
teleocidin, aplysiatoxin, and palytoxin. Adv. Cancer Res. 49, 223-264. 
Driedger, P.E. & Blumberg, P.M. (1980). Different biological targets 
for resiniferatoxin and phorbol 1 P-myristate 13-acetate. Cancer Res. 
40,1400-1404. 
Yoshida, M., Horinouchi, S. & Beppu, T. (1995). Trichostatin A and 
trapoxin: novel chemical probes for the role of histone acetylation in 
chromatin structure and function. Bioessays 17, 423-430. 
Taunton, J., Hassig, CA. & Schreiber, S.L. (1996). A mammalian 
89. 
90. 
91. 
92. 
93. 
94. 
95. 
96. 
97. 
98. 
99. 
100 
histone deacetylase related to the yeast transcriptional regulator 
Rpd3p. Science 272,408-411. 
Heby, O., Marton, L.J., Wilson, C.B. & Gray, J.W. (1977). Effect of 
methylglyoxal-bis (guanylhydrazone), an inhibitor of spermidine and 
spermine synthesis, on cell cycle traverse. Eur. J. Cancer 13, 
1009-l 017. 
Flink, I. & Pettijohn, D.E. (1975). Polyamines stabilise DNA folds. 
Nature 253, 62-63. 
Chiu, J.F. & Sung, SC. (1972). Effect of spermidine on the activity of 
DNA polymerases. Biochim. Biophys. Acta 281, 535-542. 
Rani, C.S., et al., & Shayman, J.A. (1995). Cell-cycle arrest induced by 
an inhibitor of glucosylceramide synthase. Correlation with cyclin- 
dependent kinases. J. B/o/. Chem. 270, 2859-2867. 
Zhang, H., Desai, N.N., Olivera, A., Seki, T., Brooker, G. &Spiegel, S. 
(1991). Sphingosine-l-phosphate, a novel lipid, involved in cellular 
proliferation. J. Cell Biol. 114, 155-l 67. 
Hannun, Y.A., Obeid, L.M. &Wolff, R.A. (1993). The novel second 
messenger ceramide: identification, mechanism of action, and cellular 
activity. Adv. Lipid Res. 25, 43-64. 
Obeid, L.M., Linardic, CM., Karolak, L.A. & Hannun, Y.A. (1993). 
Programmed cell death induced by ceramide. Science 259, 
1769-1771. 
Miyake, Y., Kozutsumi, Y., Nakamura, S., Fujita, T. & Kawasaki, T. 
(1995). Serine palmitovltransferase is the primary taroet of a 
sphingosine-like immunosuppressant, ISP:l /myriociny Biochem. 
Biophvs. Res. Common. 211,396-403. 
Horvaih, A., Sutterlin, C., Manning-Krieg, U., Mowa, N.R. & Riezman, 
H. (1994). Ceramide synthesis enhances transport of GPI-anchored 
proteins to the Golgi apparatus in yeast. EMBO 1. 13, 3687-3695. 
Spinozzi, F., et al., & Nicoletti, I. (1994). The natural tyrosine kinase 
inhibitor genistein produces cell-cycle arrest and apoptosis in Jurkat 
T-leukemia cells. Leuk. Res. 18, 431-439. 
Obinata, A., Akimoto, Y., Hirano, H. & Endo, H. (1991). Stimulation by 
Bt2cAMP of epidermal mucous metaplasia in retinol-pretreated chick 
embryonic cultured skin, and its inhibition by herbimycin A, an inhibitor 
for protein-tyrosine kinase. Exp. Cell Res. 193,36-44. 
Potmesil, M., et a/., & Silber, R. (1988). Resistance of human leukemic 
and normal lymphocytes to drug-induced DNA cleavage and low 
levels of DNA topoisomerase II. Cancer Res. 48,3537-3543. 
101. Sinha, B.K. (1995). Topoisomerase inhibitors. A review of their 
therapeutic potential in cancer. Drugs 49, 1 l-l 9. 
102. Rota, J., Ishida, R., Berger, J.M., Andoh, T. &Wang, J.C. (1994). 
Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by 
trapping the enzyme in the form of a closed protein clamp. Proc. Nat/. 
Acad. Sci. USA 91, 1781-I 785. 
103. Giese, G., Wiegers, W., Kubbies, M., Scherbarth, A. & Traub, P. 
(1995). Okadaic acid coinduces vimentin expression and cell-cycle 
arrest in MPC-11 mouse plasmacytoma cells. J. Cell fhysiol. 163, 
145-l 54. 
104. Afshari, C.A. & Barrett, J.C. (1994). Disruption of GO-G1 arrest in 
quiescent and senescent cells treated with phosphatase inhibitors. 
Cancer Res. 54,2317-2321. 
105. Takizawa, P.A., et al., & Malhotra, V. (1993). Complete vesiculation of 
Golgi membranes and inhibition of protein transport by a novel sea 
sponge metabolite, ilimaquinone. Cell 73, 1079-I 090. 
106. Fournier, R.E. & Pardee, A.B. (1975). Cell-cycle studies of 
mononucleate and cytochalasin-B-induced binucleate fibroblasts. 
Proc. Nat/. Acad. Sci. USA 72, 869-873. 
107. Martineau, S.N., Andreassen, P.R. & Margolis, R.L. (1995). Delay of 
HeLa cell cleavage into interphase using dihydrocytochalasin B: 
retention of a postmitotic spindle and telophase disk correlates with 
synchronous cleavage recovery. J. Ce// Biol. 131, 191-205. 
108. Uppuluri, S., Knipling, L., Sackett, D.L. & Wolff, J. (I 993). Localization 
of the colchicine-binding site of tubulin. Proc. Nat/. Acad. Sci. USA 
90, 11598-l 1602. 
109. Cortese, F., Bhattacharyya, B. & Wolff, J. (1977). Podophyllotoxin as a 
probe for the colchicine binding site of tubulin. J. Biol. Chem. 252, 
1134-l 140. 
110. Hoebeke, J., Van Nijen, G. & De Brabander, M. (1976). Interaction of 
oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. 
Biochem. Biophys. Res. Commun. 89,319-324. 
1 11. Lee, J.C., Harrison, D. & Timasheff, S.N. (1975). Interaction of 
vinblastine with calf brain microtubule protein. J. Biol. Chem. 250, 
9276-9282. 
112. Kupchan, SM., et a/., & Bryan, R.F. (1972). Maytansine, a novel 
antileukemic ansa macrolide from Maytenus ovatus. J. Am. Chem. 
Soc.94,1354-1356. 
Review Natural product inhibitors of the cell cycle Hung et al. 639 
113. Luduena, R.F., Roach, M.C., Prasad, V. & Pettit, G.R. (1993). 
Interaction of halichondrin B and homohalichondrin B with bovine 
brain tubulin. Biochem. fharmacol. 45, 421-427. 
114. Luduena, R.F., et al., & Iwasaki, S. (1994). Interaction of ustiloxin A 
with bovine brain tubulin. Biochem. Pharmacol. 47, 1593-l 599. 
115. Bai, R., Cichacz, Z.A., Herald, C.L., P&tit, G.R. & Hamel, E. (1993). 
Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural 
product that inhibits mitosis, microtubule assembly, and the binding of 
vinblastine to tubulin. Mol. Pharmacol. 44, 757-766. 
116. Dahllof, B., Billstrom, A., Cabral, F. & Hartley-Asp, B. (1993). 
Estramustine depolymerizes microtubules by binding to tubulin. 
Cancer Res. 53,4573-4581. 
117. Margolis, R.L., Rauch, C.T. &Wilson, L. (1980). Mechanism of 
colchicine-dimer addition to microtubule ends: implications for the 
microtubule polymerization mechanism. Biochemistry 19, 5550-5557. 
118. Nicolaou, K.C., Dai, W.M. & Guy, R.K. (1994). Chemistry and biology 
of taxol. Angew. Chem. Int. Ed. Engl. 33, 15-44. 
119. Jordan, M.A., Toso, R.J., Thrower, D. & Wilson, L. (1993). Mechanism 
of mitotic block and inhibition of cell proliferation by taxol at low 
concentrations. Proc. Nat/. Acad. Sci. USA 90, 9552-9556. 
120. Rieder, C.L., Schultz, A., Cole, R. & Sluder, G. (1994). Anaphase 
onset in vertebrate somatic cells is controlled by a checkpoint that 
monitors sister kinetochore attachment to the spindle. J. Cell Biol. 
127,1301-1310. 
121. Nogales, E., Wolf, S.G., Khan, LA., Luduena, R.F. & Downing, K.H. 
(1995). Structure of tubulin at 6.5 A and location of the taxol-binding 
site. Nature 375, 424-427. 
122. Andreu, J.M., et a/., & Bordas, J. (1994). Solution structure of 
Taxotere-induced microtubules to 3-nm resolution. The change in 
protofilament number is linked to the binding of the taxol side chain. J. 
Biol. Chem. 269,31785-31792. 
123. Andreu, J.M., et a/., & Towns-Andrews, E. (1992). Low resolution 
structure of microtubules in solution. Synchrotron X-ray scattering and 
electron microscopy of taxol-induced microtubules assembled from 
purified tubulin in comparison with glycerol and MAP-induced 
microtubules. J. Mol. Biol. 226, 169-l 84. 
124. Rao, S., et a/., & Horwitz, S.B. (1994). 3’-(p-azidobenzamido)taxol 
photolabels the N-terminal 31 amino acids of 6 tubulin. J. Biol. Chem. 
269,3132-3134. 
125. ter Haar, E., et a/., & Day, B.W. (1996). Discodermolide, a cytotoxic 
marine agent that stabilizes microtubules more potently than taxol. 
Biochemistry 35, 243-250. 
126. Hung, D.T., Chen, J. & Schreiber, S.L. (1996). (+)-Discodermolide 
binds to microtubules in stoichiometric ratio to tubulin dimers, blocks 
taxol binding and results in mitotic arrest. Chemistry & Biology 3, 
287-293. 
127. Boilag, D.M., eta/., &Woods, CM. (1995). Epothilones, a new class 
of microtubule-stabilizing agents with a taxol-like mechanism of action. 
Cancer Res. 55, 2325-2333. 
128. David, B., et a/., &Wright, M. (1994). Rhazinilam mimics the cellular 
effects of taxol by different mechanisms of action. Cell Motil. 
Cytoskeleton 26, 317-326. 
129. Grisham, L.M., Wilson, L. & Bensch, K.G. (1973). Antimitotic action of 
griseofulvin does not involve disruption of microtubules. Nature 244, 
294-296. 
130. Weber, K., Wehland, J. & Herzog, W. (1976). Griseofulvin interacts 
with microtubules both in viva and in vitro. J. Mol. Biol. 102, 
817-829. 
131. Kung, A.L., Zetterberg, A., Sherwood, S.W. & Schimke, R.T. (1990). 
Cytotoxic effects of cell cycle phase specific agents: result of cell 
cycle perturbation. Cancer Res. 50, 7307-7317. 
132. Sakai, T., Aoike, A., Marui, N., Kawai, K., Nishino, H. & Fukushima, M. 
(1989). Protection by cycloheximide against cytotoxicity induced by 
vincristine, colchicine, or delta 1 P-prostaglandin J2 on human 
osteosarcoma cells. Cancer Res. 49, 1 193-l 196. 
133. Donaldson, K.L., Goolsby, G.L., Kiener, P.A. & Wahl, A.F. (1994). 
Activation of o34cdc2 coincident with taxol-induced apootosis. Cell 
Growth Differentiation 5, 1041-I 050. 
134. Xu. C., Meikrantz. W.. Schleael. R. & Saaer. R. (1995). The human 
papilloma virus 16EG’gene s&itizes human mammary epithelial cells 
to apoptosis induced by DNA damage. froc. Nat/. Acad. Sci USA 92, 
7829-7833. 
135. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. (1993). p53- 
dependent apoptosis modulates the cytotoxicity of anticancer agents. 
Cell74, 957-967. 
136. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. & 
Oren, M. (1991). Wild-type p53 induces apoptosis of myeloid 
leukaemic cells that is inhibited by interleukin-6. Nature 352, 
345-347. 
137. Keith, CT. & Schreiber, S.L. (1995). PIK-related kinases: DNA repair, 
recombination, and cell cycle checkpoints. Science 270, 50-51. 
138. Kastan, M.B., et al., & Fornace, A.J., Jr. (1992). A mammalian cell cycle 
checkooint oathwav utilizina ~53 and GADD45 is defective in ataxia- 
telangiectasia. Ce/;71, 587-597. 
139. Albers. M.W., Williams, R.T.. Brown. E.J.. Tanaka, A., Hall, F.L. & 
Schreiber, S.L. (1993). FKB’P-rapamycin inhibits a cyclin-dependent 
kinase activity and a cyclin Dl -Cdk association in early Gl of an 
osteosarcoma cell line. J. B/o/. Chem. 266, 22825-22829. 
140. Gong, J., Traganos, F. & Darzynkiewicz, Z. (1995). Discrimination of 
G2 and mitotic ceils by flow cytometry based on different expression 
of cyclins A and Bl. Exp. Cell Res. 220, 226-231. 
141. Nadler, S.G., Tepper, M.A., Schacter, B. & Mazzucco, C.E. (1992). 
Interaction of the immunosuppressant deoxyspergualin with a member 
of the Hsp70 family of heat shock proteins. Science 268, 484-486. 
142. Shimada, J., Kwon, H.J., Sawamura, M. & Schreiber, S.L. (1995). 
Synthesis and cellular characterization of the detransformation agent, 
(-)-depudecin. Chemistry & Biology 2, 517-525. 
143. Crews, CM., Collins, J.L., Lane, W.S., Snapper, M.L. & Schreiber, S.L. 
(1994). GTP-dependent binding of the antiproliferative agent 
didemnin to elongation factor 10~. J. Biol. Chem. 269, 15411-l 5414. 
144. SirDeshpande, B.V. & Toogood, P.L. (1995). Mechanism of protein 
synthesis inhibition by didemnin B in vitro. Biochemistry 34, 
9177-9184. 
145. Crews, CM., Lane, W.S. & Schreiber, S.L. (1996). Didemnin binds to 
the protein palmitoyl thioesterase responsible for infantile neuronal 
ceroid lipofuscinosis. Proc. Nat/. Acad. Sci. USA 93, 4316-4319. 
146. Nishi, K.‘, Yoshida, M., Fujiwara, D., Nishikawa, M., Horinouchi, S. & 
Beppu, T. (1994). Leptomycin B targets a regulatory cascade of crml , 
a fission yeast nuclear protein, involved in control of higher order 
chromosome structure and gene expression. J. Biol. Chem. 269, 
6320-6324. 
147. Kinnel, R.B. & Gehrken, H.P. (1993). Palau’amine: a cytotoxic and 
immunosuppressive hexacyclic bisguanidine antibiotic from the 
sponge Stylotella agminata. J. Am. Chem. Sot. 115, 3376-3377. 
148. Lindquist, N., Fenical, W., Van Duyne, G.D. & Clardy, J. (1991). 
Isolation and structure determination of diazonamides A and B, 
unusual cytotoxic metabolites from the marine ascidian Diazona 
chinensis. J. Am. Chem. Sot. 113,2303-2304. 
